This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| abacavir | |
|---|---|
| Name | Abacavir |
| Tradename | Ziagen, Epzicom (with lamivudine), Trizivir (with zidovudine and lamivudine) |
| Routes of administration | Oral |
| Class | Nucleoside reverse transcriptase inhibitor |
| CAS number | 136470-78-5 |
| ATC prefix | J05 |
| ATC suffix | AF05 |
abacavir is an antiretroviral medication used to treat human immunodeficiency virus infection. It is commonly administered in fixed-dose combinations alongside agents such as zidovudine and lamivudine or with lamivudine and dolutegravir, and forms part of many treatment regimens recommended by global health organizations. Its clinical utility is balanced by a distinct hypersensitivity reaction linked to a genetic marker and by established resistance pathways documented in virology and pharmacology literature.
Abacavir is prescribed for adults and children infected with Human immunodeficiency virus, typically as part of combination therapy together with agents from classes represented by Zidovudine, Lamivudine, Tenofovir disoproxil, Emtricitabine, Dolutegravir, and Efavirenz. Treatment guidelines from organizations such as the World Health Organization, the United States Department of Health and Human Services, and the European AIDS Clinical Society include regimens that incorporate abacavir in first-line or alternative therapy for certain patient populations, including those with coexisting conditions considered by panels like the U.S. Public Health Service and committees convened by the Joint United Nations Programme on HIV/AIDS. Abacavir-containing combinations have been evaluated in landmark clinical trials coordinated by networks including the ACTG and the INSIGHT group, and are considered for patients with renal impairment when compared to regimens involving agents studied by groups such as the National Institute of Allergy and Infectious Diseases.
Abacavir is a guanosine analogue that requires intracellular phosphorylation to the active carbocyclic triphosphate form by cellular kinases characterized in molecular studies affiliated with institutions such as Harvard Medical School, University of Oxford, and the National Institutes of Health. The active metabolite competitively inhibits the reverse transcriptase enzyme of Human immunodeficiency virus type 1 by incorporation into viral DNA, leading to DNA chain termination; mechanistic insights have been elucidated in structural biology work performed at centers like the European Molecular Biology Laboratory and the Max Planck Institute. Reverse transcriptase inhibition by nucleoside analogues is a cornerstone concept advanced in scholarship from laboratories associated with Cold Spring Harbor Laboratory and researchers awarded by bodies such as the Lasker Award and the Nobel Prize in Physiology or Medicine for related discoveries.
After oral administration, abacavir is absorbed with bioavailability characterized in pharmacology studies from academic centers including Johns Hopkins University and Imperial College London. Hepatic metabolism via alcohol dehydrogenase and glucuronyl transferases has been described in pharmacokinetic reports from institutions like the University of California, San Francisco and the Mayo Clinic. Plasma protein binding and distribution data derive from clinical pharmacology research undertaken at hospitals such as Massachusetts General Hospital and Guy's Hospital. Elimination pathways and half-life determinations have been included in regulatory submissions to agencies including the Food and Drug Administration and the European Medicines Agency, and pediatric pharmacokinetic profiling has been performed in multicenter trials coordinated by consortia like the PENTA network.
The most clinically significant adverse event is a potentially life-threatening hypersensitivity reaction strongly associated with the HLA-B*57:01 allele identified through genetic epidemiology studies led by groups at Stanford University, University College London, and the Wellcome Trust Sanger Institute. Screening for HLA-B*57:01 prior to initiating therapy is recommended by bodies including the Clinical Pharmacogenetics Implementation Consortium, American College of Physicians, and national agencies such as the Therapeutic Goods Administration and the Health Canada. Common adverse effects reported in phase III trials run by cooperative groups such as the DART trial include fever, fatigue, nausea, and headache; long-term observational studies from cohorts like the EuroSIDA study have examined cardiovascular events and metabolic effects. Case reports and surveillance from systems such as the Vaccine Adverse Event Reporting System and pharmacovigilance programs of manufacturers have informed labeling and risk-minimization measures.
Drug interaction profiles have been characterized in clinical pharmacology collaborations involving the European Medicines Agency, the FDA, and academic centers such as Yale School of Medicine; interactions with alcohol and agents metabolized by alcohol dehydrogenase or glucuronyl transferases are noted. Co-administration with enzyme inducers or inhibitors evaluated in trials sponsored by consortia like the AIDS Clinical Trials Group and pharmaceutical firms can alter exposure, and care is taken when combining with protease inhibitors studied at institutions such as Roche-funded trials or non-nucleoside reverse transcriptase inhibitors assessed at GlaxoSmithKline studies. Drug interaction checkers used in clinical settings such as those implemented by World Health Organization treatment programs and hospital formularies reflect evidence collected in pharmacokinetic interaction studies.
Resistance mutations affecting susceptibility have been mapped in molecular surveillance projects run by the Stanford HIV Drug Resistance Database, the Los Alamos National Laboratory HIV databases, and networks like the International AIDS Society–USA panels. Mutations in the reverse transcriptase gene such as those catalogued by investigators at University of Cambridge and McGill University reduce susceptibility to guanosine analogues; epidemiological tracking in cohorts like MACS and WIHS has documented transmitted and acquired resistance patterns. Resistance testing is recommended by treatment guidelines from the British HIV Association and the International Antiviral Society–USA to inform regimen selection.
Abacavir was discovered and developed in medicinal chemistry programs at pharmaceutical companies collaborating with academia, with key development activities undertaken by teams affiliated with firms such as GlaxoSmithKline and smaller biotech partners. Clinical development included randomized trials overseen by cooperative groups like the AIDS Clinical Trials Group and regulatory review by the Food and Drug Administration and European Medicines Agency, leading to approvals and postmarketing requirements. The association of HLA-B*57:01 with hypersensitivity emerged from genetic studies conducted at institutions including Royal Free Hospital, Stanford University, and consortia supported by the Wellcome Trust, leading to implementation of pharmacogenetic screening practices worldwide and influencing regulatory policy and clinical guidelines compiled by organizations such as the World Health Organization and the International Conference on Harmonisation.
Category:Antiretroviral drugs